Allogene Therapeutics, Inc. (ALLO)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.250.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Allogene Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	2,500
EPS	—	-0.152
FY 2026 · Annual
Revenue	—	3.82M
EPS	—	-0.601
Operating expenses	$210M–$225MGAAP	—
FY 2027 · Annual
Revenue	—	13.43M
EPS	—	-0.636

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Successful CEO transition to Zachary Roberts	A supporting condition in Allogene Therapeutics, Inc.'s published investment case. The stated target is Stable leadership with positive strategic progress.	Improving	CEO transition leads to strategic setbacks or loss of confidence	Qualitative: RMAT/Fast Track granted, ALPHA3 expansion to ~100 sites FDA granted RMAT and Fast Track for cema-cel; company plans ~100 ALPHA3 sites by year-end; Q1 revenue missed but Q2 beat. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management announced the CEO transition with Zachary Roberts appointed as President and CEO, succeeding David Chang. This leadership change was formally disclosed in 2026-Q2 and is a one-time event with no financial metrics directly tied to it in the disclosures. Delivery assessment Oct 24, 2026
Manage operating expenses within $210M-$225M range in 2026	Allogene aims to control operating expenses within $210M-$225M in 2026.	Intact	operating expenses exceed $225 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management updated 2026 operating expense guidance from approximately $150 million cash expense and $210 million GAAP expense to approximately $165 million cash expense and $225 million GAAP expense including stock-based compensation. Actual operating expenses remain high with quarterly operating losses around $46 million in 2026-Q1 and Q2. The trajectory shows modestly increasing expense guidance consistent with management's statements. Delivery assessment Oct 24, 2026
Achieve revenue near $6 billion in 2026	A primary condition in Allogene Therapeutics, Inc.'s published investment case. The stated target is ~6 billion USD.	Broken	revenue falls significantly below $6 billion in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.64

$-0.76 → $-0.64 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.76	$11,625,800	7 / 6
2026-07-25	$-0.76	$11,625,800	7 / 6
2026-07-26	$-0.76	$11,625,800	7 / 6
2026-07-27	$-0.76	$11,625,800	7 / 6
2026-07-28	$-0.76	$11,625,800	7 / 6
2026-07-29	$-0.68	$14,594,750	6 / 8
2026-07-30	$-0.68	$14,594,750	6 / 8
2026-07-31	$-0.68	$14,594,750	6 / 8
2026-08-01	$-0.68	$14,594,750	6 / 8
2026-08-02	$-0.68	$14,594,750	6 / 8
2026-08-03	$-0.68	$14,594,750	6 / 8
2026-08-04	$-0.68	$14,594,750	6 / 8
2026-08-05	$-0.68	$14,594,750	6 / 8
2026-08-06	$-0.68	$14,594,750	6 / 8
2026-08-07	$-0.76	$11,625,800	6 / 5
2026-08-08	$-0.68	$14,594,750	6 / 8
2026-08-09	$-0.68	$14,594,750	6 / 8
2026-08-10	$-0.68	$14,594,750	6 / 8
2026-08-11	$-0.68	$14,594,750	6 / 8
2026-08-12	$-0.68	$14,594,750	6 / 8
2026-08-13	$-0.68	$14,594,750	6 / 8
2026-08-14	$-0.76	$11,625,800	6 / 5
2026-08-15	$-0.76	$11,625,800	7 / 5
2026-08-16	$-0.76	$11,625,800	6 / 6
2026-08-17	$-0.76	$11,625,800	6 / 6
2026-08-18	$-0.76	$11,625,800	6 / 6
2026-08-19	$-0.76	$11,625,800	7 / 6
2026-08-20	$-0.76	$11,625,800	7 / 6
2026-08-21	$-0.64	$12,085,800	7 / 7
2026-08-22	$-0.64	$12,085,800	7 / 7
2026-08-23	$-0.64	$13,428,667	7 / 7
2026-08-24	$-0.64	$13,428,667	7 / 7
2026-08-25	$-0.64	$13,428,667	7 / 7
2026-08-26	$-0.64	$13,428,667	7 / 7
2026-08-27	$-0.64	$13,428,667	7 / 7
2026-08-28	$-0.64	$13,428,667	7 / 7
2026-08-29	$-0.64	$13,428,667	7 / 7
2026-08-30	$-0.64	$13,428,667	7 / 7
2026-08-31	$-0.64	$13,428,667	7 / 7
2026-09-01	$-0.64	$13,428,667	7 / 7
2026-09-02	$-0.64	$13,428,667	7 / 7
2026-09-03	$-0.64	$13,428,667	7 / 7
2026-09-04	$-0.64	$13,428,667	7 / 7
2026-09-05	$-0.64	$13,428,667	6 / 7
2026-09-06	$-0.64	$13,428,667	6 / 7
2026-09-07	$-0.64	$13,428,667	6 / 7
2026-09-08	$-0.64	$13,428,667	6 / 7
2026-09-09	$-0.64	$13,428,667	6 / 7
2026-09-10	$-0.64	$13,428,667	6 / 7
2026-09-11	$-0.64	$13,428,667	6 / 7
2026-09-12	$-0.64	$13,428,667	6 / 7
2026-09-13	$-0.64	$13,428,667	6 / 7
2026-09-14	$-0.64	$13,428,667	6 / 7
2026-09-15	$-0.64	$13,428,667	6 / 7
2026-09-16	$-0.64	$13,428,667	6 / 7
2026-09-17	$-0.64	$13,428,667	6 / 7
2026-09-18	$-0.64	$13,428,667	6 / 7
2026-09-19	$-0.64	$13,428,667	6 / 7
2026-09-20	$-0.64	$13,428,667	6 / 7
2026-09-21	$-0.64	$13,428,667	6 / 7
2026-09-22	$-0.64	$13,428,667	6 / 7
2026-09-23	$-0.64	$13,428,667	6 / 7
2026-09-24	$-0.64	$13,428,667	6 / 7
2026-09-25	$-0.64	$13,428,667	6 / 7
2026-09-26	$-0.64	$13,428,667	6 / 7
2026-09-27	$-0.64	$13,428,667	6 / 7
2026-09-28	$-0.64	$13,428,667	6 / 7
2026-09-29	$-0.64	$13,428,667	6 / 7
2026-09-30	$-0.64	$13,428,667	6 / 7
2026-10-01	$-0.64	$13,431,111	6 / 7
2026-10-02	$-0.64	$13,431,111	6 / 7
2026-10-03	$-0.64	$13,431,111	6 / 7
2026-10-04	$-0.64	$13,431,111	6 / 7
2026-10-05	$-0.64	$13,431,111	6 / 7
2026-10-06	$-0.64	$13,431,111	6 / 7
2026-10-07	$-0.64	$13,431,111	6 / 7
2026-10-08	$-0.64	$13,431,111	6 / 7
2026-10-09	$-0.64	$13,431,111	6 / 7
2026-10-10	$-0.64	$13,431,111	6 / 7
2026-10-11	$-0.64	$13,431,111	6 / 7
2026-10-12	$-0.64	$13,431,111	6 / 7
2026-10-13	$-0.64	$13,431,111	6 / 7
2026-10-14	$-0.64	$13,431,111	6 / 7
2026-10-15	$-0.64	$13,431,111	6 / 7
2026-10-16	$-0.64	$13,431,111	6 / 7
2026-10-17	$-0.64	$13,431,111	6 / 7
2026-10-18	$-0.64	$13,431,111	6 / 7
2026-10-19	$-0.64	$13,431,111	6 / 7
2026-10-20	$-0.64	$13,431,111	6 / 7
2026-10-21	$-0.64	$13,431,111	6 / 7
2026-10-22	$-0.64	$13,431,111	6 / 7
2026-10-23	$-0.64	$13,431,111	6 / 7
2026-10-24	$-0.64	$13,431,111	6 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	13	2
2026-06-01	12	2
2026-07-01	11	2
2026-08-01	11	1
2026-09-01	11	1
2026-10-01	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage operating expenses within $210M-$225M range in 2026Direct metric needs a verified mapping
Achieve revenue near $6 billion in 2026Published status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-59.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Allogene Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk clinical-stage biotechnology company, with its longer-term case depending on successful trial progress rather than current earnings. Management has advanced key programs, but the long-term thesis remains uncertain because the business is loss-making and recent performance trails its industry cohort.

What's priced into Allogene Therapeutics, Inc.

ALLO is expensive versus peers, with valuation supported partly by the possibility that its programs create future opportunities. The model’s confidence is low, and the evidence says the valuation reflects expensive pricing alone, not a broader mix of weak fundamentals and turbulent conditions.

What the fundamentals likely do

Near term, operating losses are likely to remain material: quarterly losses were about $46 million in the first two quarters of 2026, and expense guidance rose to about $165 million in cash costs and $225 million under standard accounting. Management reports progress in the ALPHA3 and RESOLUTION trials, but a guidance cut, industry execution risks, and the next clinical updates remain important near-term tests.

What Allogene Therapeutics, Inc. hinges on

Over the multi-year view, the thesis depends on enrollment and trial progress, including the expected ALPHA3 interim analysis in mid-2027 and the planned ALLO-329 update in Q4 2026. Weaker guidance or deteriorating employment data could weigh on the near-term business backdrop, while continued strength among healthcare sector leaders could support sector sentiment.